REG - Futura Medical PLC - Remuneration of Non-Executive Directors and TVR

Futura MedicalAnnouncement

13/01/2022 10:35

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220113:nRSM3634Ya&default-theme=true

RNS Number : 3634Y  Futura Medical PLC  13 January 2022

13 January 2022

  Futura Medical plc

("Futura" or the "Company")

Remuneration of Non-Executive Directors and Total Voting Rights

 

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products for sexual health and pain relief, announces the issue
of 145,556 new ordinary shares of 0.2 pence each ("Ordinary Shares") in
respect of the 2021 remuneration of its Non-Executive Directors.

 

In accordance with the terms of their service agreements, John Clarke,
Non-Executive Director, and Jonathan Freeman, former Non-Executive Director,
receive 25-30 per cent of their remuneration in the form of Ordinary Shares.
For 2021, these were issued at 14.97 pence per share, being the average
closing mid-market price of the last 10 trading days of 2020 (as announced via
RNS on 14 April 2021).

 

The 145,556 new Ordinary Shares shall rank pari passu with the existing issued
Ordinary Shares and have been issued to the Non-Executive Directors as
follows:

 

 Director           Number of Ordinary Shares issued for 2021 remuneration  Total number of Ordinary Shares held  Percentage of the Company's resulting issued share capital
 John Clarke        107,998                                                 750,540                               0.26%
 Jonathan Freeman*  37,558                                                  259,840                               0.09%

 

* Stepped down from the Board on 31 December 2021

 

The shares element of the Non-Executive Directors' remuneration for 2022 will
be awarded at 36.36 pence per Ordinary Share, being the average closing
mid-market price for the last 10 trading days of 2021. In addition, Jeff
Needham will be awarded shares at 37.31 pence per Ordinary Share, being the
average closing mid-market price in the 10 trading days prior to his
appointment on 8 October 2021, in respect of the shares element of his
pro-rata remuneration since appointment. These Ordinary Shares are expected to
be issued in January 2023.

 

Full details of the Non-Executive Directors' remuneration is included in the
Company's Annual Report & Accounts.

Total Voting Rights

Application has been made to the London Stock Exchange and it is anticipated
that trading of the new Ordinary Shares will commence on AIM at 8:00 am on 18
January 2022.

 

Immediately following the above issue, the Company will have 287,296,527
Ordinary Shares in issue, each carrying one voting right. Since the Company
currently holds no Ordinary Shares in treasury, the total number of voting
rights in the Company is therefore 287,296,527 and this figure may be used by
Shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change in
their interest in, the share capital of the Company under the FCA's Disclosure
Guidance and Transparency Rules.

 

ENDS

 

 

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

www.Futuramedical.com (http://www.Futuramedical.com)

 

Nominated Adviser and Sole Broker:

Liberum

Richard Lindley/ Benjamin Cryer/ Kane Collings

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 20 3922 0891

 

Notes to editors

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Current therapeutic areas are sexual
health, including erectile dysfunction, and pain relief. Development and
commercialisation strategies are designed to maximise product differentiation
and value creation whilst minimising risk.

 

MED3000 is Futura's topical gel formulation that is a breakthrough treatment
for erectile dysfunction (ED) through a unique evaporative mode of action.
Futura has conducted a Phase 3 study using MED3000 in ED, referred to as
"FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised,
double blind, placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment baseline,
consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3
(internationally accepted clinical trial endpoints in ED) with over 60% of
patients experiencing a clinically meaningful improvement in their ED.
MED3000 also begins to work immediately in some patients, with 60% of patients
seeing onset of their erection within 10 minutes of application. MED3000 is CE
marked in Europe and the UK as a clinically proven topical treatment
for adult men with erectile dysfunction.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com

 

The notification below is made in accordance with Article 19 of the EU Market
Abuse Regulation 596/2014.

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         John Clarke

 2    Reason for the notification
 a)   Position/status                                              Director/ PDMR

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Futura Medical plc

 b)   LEI                                                          21380053QLT46UNV2303

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument

                                                                   Ordinary shares of 0.2p each

      Identification code

                                                                   GB0033278473
 b)   Nature of the transaction                                    Issue of shares

 c)   Price(s) and volume(s)

Price(s)     Volume(s)

                                                                   14.97 pence  107,998
 d)   Aggregated information

      - Aggregated volume

                                                                   Not applicable

      - Price

 e)   Date of the transaction                                      13 January 2022

 f)   Place of the transaction                                     Outside of trading venue

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

13 January 2022

f)

 

Place of the transaction

 

Outside of trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBXLFFLFLXBBB